Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Correction of high myopic astigmatism with small incision lenticule extraction (ReLEx SMILE)

Poster Details

First Author: J.Grzeszkowiak POLAND

Co Author(s):                        

Abstract Details

Purpose:

To evaluate the outcome after small incision refractive lenticule extraction (ReLEx SMILE) in patients with high myopic astigmatism (-3,0 to -5,0 D).

Setting:

All preoperative and postoperative tests and measurements as well as laser treatments were performed at Optegra Eye Clinic in Poznan, Poland

Methods:

47 eyes with high myopic astigmatism (�â�‰�¥ -3,0 D) were enrolled for the study. Patients were examined before, 2 and 8 months after surgery. None of the patients have shown any signs of clinical or subclinical forms of keratoconus. In all cases ReLEx SMILE treatments were performed with a Visumax femtosecond laser (Carl Zeiss Meditec, Germany).

Results:

The preoperative SEQ was -6,27�Â�±1,81D(-3,13 to -9,75D). 2 months the SEQ was -0,14�Â�±0,53D(-1,75 to �,88D) and was within 0,50D of emmetropia in 79%. The sphere was reduced from -4,35�Â�±1,87D(-1,25 to -7,25D) to �,16�Â�±0,59D(-1,75 to �,50D). The astigmatism was reduced from -3,72�Â�±0,75D(-3,00 to -5,00D) to -0,60�Â�±0,48D(-2,75 to 0,00D). A gain of �â�‰�¥1 lines was observed in 34% of eyes. 8 months the SEQ was �,15�Â�±0,42D(-1,75 to �,50D) and was within 0,50D of emmetropia in 89%. The sphere was �,05�Â�±0,45D(-1,50 to �,75D). The astigmatism was -0,38�Â�±0,47D(-2,50 to 0,00D).A gain of �â�‰�¥1 lines was observed in 57% of eyes.

Conclusions:

The small incision refractive lenticule extraction (ReLEx SMILE) is a predictable method of correction of SEQ in high myopic astigmatism. The trend line shows that tendency to undercorrection of the astigmatic error increases with the attempted treatment. The treatment contributed to the gain of 1 or more lines of postoperative BCVA for the majority of patients.

Financial Disclosure:

NONE

Back to Poster listing